ABSTRACT
We report a case of gallbladder cancer and right breast cancer associated with pancreaticobiliary maljunction.The patient was a 74-year-old woman who presented with abdominal pain due to cholecystitis.Abdominal CT detected a gallbladder tumor and right breast tumor.Enhanced CT and MRCP examination revealed gallbladder cancer and right breast cancer associated with pancreaticobiliary maljunction.We performed a gallbladder bed resection, bile duct resection, and right total mastectomy.The histopathological diagnosis of the gallbladder was moderately tubular adenocarcinoma and that of the breast tumor was scirrhous carcinoma.The patient remains recurrence-free 8 months after surgery.
Subject(s)
Adenocarcinoma, Scirrhous , Adenocarcinoma , Breast Neoplasms/pathology , Gallbladder Neoplasms/pathology , Neoplasms, Multiple Primary/pathology , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/surgery , Adenocarcinoma, Scirrhous/diagnostic imaging , Adenocarcinoma, Scirrhous/surgery , Aged , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/surgery , Cholecystectomy , Female , Gallbladder Neoplasms/diagnostic imaging , Gallbladder Neoplasms/surgery , Humans , Mastectomy , Neoplasms, Multiple Primary/diagnostic imaging , Neoplasms, Multiple Primary/surgery , Tomography, X-Ray ComputedABSTRACT
A 76-year-old man noticed a tumor under his right nipple. Mammography revealed an irregularly shaped nodule in the right breast. Ultrasonography showed a 20mm irregularly shaped nodule in the central area. MRI showed an 18mm irregularly shaped nodule in the central area with skin invasion. On core needle biopsy, the tumor was diagnosed as an invasive ductal carcinoma of the right breast. The patient underwent a mastectomy and axillary lymph node dissection. Histopathologically, the patient was diagnosed with invasive ductal carcinoma(scirrhous carcinoma). The tumor was positive for both ER and PgR, and the HER2 score was 1. The Ki-67 index was 20-30%. Male breast carcinoma accounts for approximately 1.0% of all breast carcinomas. The most common complaint is elastic, hard nodules with no pain. Postoperative therapy for male breast cancer is similar to that for female cancer. This patient underwent a mastectomy and lymph node dissection. After surgery, tamoxifen was administered as adjuvant therapy. There has been no evidence of recurrence for 4 months after the surgery.
Subject(s)
Adenocarcinoma, Scirrhous , Breast Neoplasms, Male/pathology , Adenocarcinoma, Scirrhous/diagnostic imaging , Adenocarcinoma, Scirrhous/secondary , Adenocarcinoma, Scirrhous/surgery , Aged , Axilla/pathology , Biopsy, Large-Core Needle , Breast Neoplasms, Male/diagnostic imaging , Breast Neoplasms, Male/surgery , Humans , Lymph Node Excision , Lymphatic Metastasis , Male , Mammography , Mastectomy , Neoplasm InvasivenessABSTRACT
The present patient was a 53-year-old female diagnosed as gastric cancer with peritoneal dissemination by staging laparoscopy. She was treated with chemotherapy using S-1 (80 mg/body/day) and CDDP (80 mg/body/day, day 8) administered for 3 weeks followed by a drug-free 2 weeks, in five-week courses. Stable disease (SD) was obtained after six courses, and then she underwent second-staging laparoscopy. Because of disappearing peritoneal disseminated nodules both macroscopically and histologically, she underwent curative total gastrectomy with D2 lymph node dissection and reconstruction by the Roux-en Y method. The postoperative pathological findings showed T2 (se) N1M0, stage IIIa and chemotherapy effective evaluation demonstrated Grade 1b. Postoperatively, S-1/CDDP therapy was carried out, after two cycles she suffered from anorexia, and then S-1 only was given. Fourteen months later, peritoneal dissemination developed. Despite changes in the regimen such as docetaxel or CPT-11, she died 23 months after the initial gastrectomy.
Subject(s)
Adenocarcinoma, Scirrhous/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/therapeutic use , Oxonic Acid/therapeutic use , Peritoneal Neoplasms/drug therapy , Stomach Neoplasms/drug therapy , Tegafur/therapeutic use , Adenocarcinoma, Scirrhous/diagnostic imaging , Adenocarcinoma, Scirrhous/pathology , Adenocarcinoma, Scirrhous/surgery , Cisplatin/administration & dosage , Drug Combinations , Fatal Outcome , Female , Gastrectomy , Humans , Middle Aged , Neoadjuvant Therapy , Oxonic Acid/administration & dosage , Peritoneal Neoplasms/diagnostic imaging , Peritoneal Neoplasms/secondary , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Tegafur/administration & dosage , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: We reviewed the radiologic features of 15 patients with orbital metastases originating from breast cancer. METHODS: This was a retrospective consecutive case series. Fifteen consecutive patients with orbital metastases originating from breast carcinoma were identified between March 1997 and September 2008. A retrospective chart review was carried out, and the radiologic findings were reviewed. RESULTS: The metastases were preseptal in 53%, intraconal in 60%, and both intraconal and extraconal in 33%. Lacrimal gland enlargement was noted in 33%, episcleral space involvement in 33%, bone involvement in 13%, and globe dystopia in 53%. The extraocular muscles were involved in 87%; in 60%, two or more muscles were involved. The medial and lateral rectus muscles were affected in 53% and 47%, respectively, and the inferior and superior rectus muscles in 33%. In 47% one or more radiologic features had not been noted by the radiologist, and in 20% the findings were misinterpreted as an"orbital pseudotumor." CONCLUSION: Orbital metastases originating from breast cancer may present heterogeneously. Orbital imaging most commonly shows unilateral and multifocal involvement of multiple extraocular muscles and intraconal and preseptal areas by an irregular lesion.
Subject(s)
Breast Neoplasms/diagnosis , Magnetic Resonance Imaging , Orbital Neoplasms/diagnosis , Orbital Neoplasms/secondary , Tomography, X-Ray Computed , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Adenocarcinoma/secondary , Adenocarcinoma, Scirrhous/diagnosis , Adenocarcinoma, Scirrhous/diagnostic imaging , Adenocarcinoma, Scirrhous/pathology , Adult , Aged , Aged, 80 and over , Biopsy , Breast Neoplasms/pathology , Diagnosis, Differential , Eye Diseases/diagnosis , Eye Diseases/pathology , Female , Humans , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Orbit/pathology , Orbital Neoplasms/pathology , Retrospective Studies , Vision Disorders/diagnosis , Vision Disorders/pathologyABSTRACT
A 67-year-old woman with debilitation and massive ascites was admitted to our hospital and diagnosed with stage IV scirrhous gastric cancer with peritoneal dissemination. After successful nasojejunal tube feeding because of oral intake disability, TS-1 combined with paclitaxel chemotherapy was selected. TS-1 at 80mg/m2 was given daily via nasojejunal tube for 2 weeks, followed by a 1-week rest, and paclitaxel at 50mg/m2 was administered intravenously on day 1 and 8. There were no serious side effects. After 4 cycles, a partial response was observed and percutaneous transesophageal gastrotubing (PTEG) was placed. After the fifth cycle, she was transferred to her home and received chemotherapy in an outpatient clinic. After 7 cycles, the disease progressed, and TS-1 combined with low-dose cisplatin was administered for 3 cycles. However, the patient died 16 weeks after discharge. PTEG was useful not only for a route of TS-1 administration, but also for receiving chemotherapy at home to maintain her quality.
Subject(s)
Adenocarcinoma, Scirrhous/drug therapy , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Gastrostomy/methods , Intubation, Gastrointestinal/methods , Stomach Neoplasms/drug therapy , Adenocarcinoma, Scirrhous/diagnostic imaging , Aged , Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Agents, Phytogenic/administration & dosage , Cisplatin/administration & dosage , Drug Combinations , Fatal Outcome , Female , Humans , Jejunum , Oxonic Acid/administration & dosage , Paclitaxel/administration & dosage , Severity of Illness Index , Stomach Neoplasms/diagnostic imaging , Tegafur/administration & dosage , Tomography, X-Ray ComputedABSTRACT
OBJECTIVE: Our objective was to study the presence of a characteristic appearance of metastatic disease to the gastrointestinal tract on contrast-enhanced CT in patients with known malignancies and to investigate its clinical implications. CONCLUSION: Twenty-five patients with scirrhous metastases had a malignant CT target sign. Careful observation and correlation with clinical history are required to differentiate this unique sign from a benign target sign.
Subject(s)
Adenocarcinoma, Scirrhous/diagnostic imaging , Adenocarcinoma, Scirrhous/secondary , Gastrointestinal Neoplasms/diagnostic imaging , Gastrointestinal Neoplasms/secondary , Tomography, X-Ray Computed/methods , Adult , Aged , Contrast Media , Female , Humans , Male , Middle Aged , Reference Standards , Retrospective StudiesABSTRACT
OBJECTIVE: To compare the CT and pathologic features and the long-term results of scirrhous hepatocellular carcinoma (HCC) after a curative resection with those of usual HCC. METHODS: Twenty-one patients with a scirrhous HCC and 296 patients with a usual HCC underwent contrast-enhanced triple-phase helical CT examinations before and after the curative resection. The CT and pathological features of scirrhous HCC, along with the cumulative survival and recurrence rates after the curative resection using a Kaplan-Meier method were compared with those of a usual HCC. RESULTS: The common CT features of scirrhous HCC were an ill-defined tumor margin (76%), peripheral rim-like enhancement on arterial and portal phases (62%), presence of area of prolonged and delayed enhancement on equilibrium phase (95%), and hepatic surface retraction (59%) and the uncommon CT features were presence of washout area (19%) and tumor capsule enhancement (5%), which were significantly different from those of usual HCC (p<0.05). Pathologically, the tumor capsule formation (29%) and tumor necrosis or hemorrhage (10%) were significantly less than those (81% and 43%, respectively) in usual HCC (p<0.05), while portal or hepatic vein involvement (33%) was significantly more common than in usual HCC (9%) (p<0.05). There were no statistically significant differences in the 5-year cumulative survival and recurrence rates between the two groups (p>0.05). CONCLUSION: Scirrhous HCC showed distinct CT and pathologic features from those of usual HCC. After the curative resection, the long-term results of scirrhous and usual HCCs were not significantly different.
Subject(s)
Adenocarcinoma, Scirrhous/diagnostic imaging , Adenocarcinoma, Scirrhous/surgery , Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/surgery , Hepatectomy , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/surgery , Adenocarcinoma, Scirrhous/pathology , Carcinoma, Hepatocellular/pathology , Female , Humans , Liver Neoplasms/pathology , Longitudinal Studies , Male , Middle Aged , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
We report a case of advanced scirrhous gastric cancer treated by operation and chemotherapy for over four years. The patient was a 54-year-old female who had suffered from gastric cancer with esophageal invasion. She underwent total gastrectomy with D2 dissection. Operative findings revealed peritoneal dissemination, and it resulted in non-curative resection. After surgery, combination chemotherapy with low-dose CDDP administered intraperitoneally and S-1, combination chemotherapy with paclitaxel and 5-FU, and then combination chemotherapy with docetaxel and S-1 were sequentially performed. She also underwent palliative surgery for intestinal obstruction resulting from carcinomatous peritonitis. She achieved long survival with good quality of life (QOL) by multidisciplinary therapy of chemotherapy and surgical operation.
Subject(s)
Adenocarcinoma, Scirrhous/drug therapy , Adenocarcinoma, Scirrhous/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Esophageal Neoplasms/secondary , Peritoneal Neoplasms/secondary , Stomach Neoplasms/drug therapy , Stomach Neoplasms/pathology , Adenocarcinoma, Scirrhous/diagnostic imaging , Adenocarcinoma, Scirrhous/surgery , Biomarkers, Tumor/blood , Esophageal Neoplasms/diagnostic imaging , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/surgery , Female , Humans , Middle Aged , Neoplasm Invasiveness/pathology , Palliative Care , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/surgery , Radiography , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/surgery , Treatment FailureABSTRACT
A 71-year-old male, who complicated of abdominal distension, was diagnosed as scirrhous gastric cancer. We treated him with the oral anticancer drug S-1 and achieved long-term stable disease over three years.
Subject(s)
Adenocarcinoma, Scirrhous/drug therapy , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Oxonic Acid/administration & dosage , Oxonic Acid/therapeutic use , Peritoneal Neoplasms/drug therapy , Stomach Neoplasms/drug therapy , Tegafur/administration & dosage , Tegafur/therapeutic use , Adenocarcinoma, Scirrhous/diagnostic imaging , Adenocarcinoma, Scirrhous/pathology , Adenocarcinoma, Scirrhous/surgery , Administration, Oral , Aged , Drug Combinations , Gastroscopy , Humans , Male , Peritoneal Neoplasms/diagnostic imaging , Peritoneal Neoplasms/secondary , Peritoneal Neoplasms/surgery , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Time Factors , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Positron emission tomography (PET) is a non-invasive imaging modality used in the diagnosis and staging of breast cancer. However, several factors can affect fluoro-deoxyglucose (FDG) uptake by a tumor. To clarify the parameters that most affect FDG accumulation in tumors, the relationship between standardized uptake values (SUVs) and clinicopathological factors and immunohistopathological analysis was investigated in breast cancer. MATERIAL AND METHODS: PET studies were performed preoperatively on 37 patients with breast carcinoma. SUVs were counted at one hour (early phase) and at two hours (delayed phase) after FDG injection. The relationships between SUVs and 13 clinical, pathological and immunohistchemical factors were studied. RESULTS: A significant association was found between FDG accumulation and early and delayed phase mitotic counts (p=0.0018 and 0.0010, respectively), Ki67 positive cell percentage (p=0.0098 and 0.0062, respectively), and nuclear grade (p=0.0232 and 0.0195, respectively). On the other hand, nodal status weakly correlated with the delayed phase (p=0.0907). However, other clinicopathological parameters and immunohistopathological status, which included tumor size, age, histology, estrogen receptor, progesterone receptor and Her2/neu overexpression, did not correlate significantly with FDG uptake. CONCLUSION: Mitotic count and Ki67 reflect cellular aggressiveness. These parameters were strongly correlated with tracer uptake. Thus our data suggested that the biological behavior of breast cancer is reflected in the variation of FDG uptake by the tumor. However, whether FDG uptake is a true prognostic and predictive factor remains to be confirmed in larger studies over an extended period of time.
Subject(s)
Breast Neoplasms/diagnostic imaging , Breast Neoplasms/metabolism , Fluorodeoxyglucose F18/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Adenocarcinoma, Scirrhous/diagnostic imaging , Adenocarcinoma, Scirrhous/metabolism , Adenocarcinoma, Scirrhous/pathology , Adult , Aged , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/diagnostic imaging , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Ductal, Breast/pathology , Female , Fluorodeoxyglucose F18/administration & dosage , Humans , Injections, Intravenous , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Neoplasms, Hormone-Dependent/diagnostic imaging , Neoplasms, Hormone-Dependent/metabolism , Neoplasms, Hormone-Dependent/pathology , Positron-Emission Tomography , Radiopharmaceuticals/administration & dosage , Receptor, ErbB-2 , Receptors, Estrogen , Receptors, ProgesteroneABSTRACT
RATIONALE AND OBJECTIVES: Our goals were to apply perfusion CT technique to breast tumor and to evaluate the correlation between arterial perfusion value and other tumor characteristics. MATERIALS AND METHODS: Thirty-one female patients with primary breast tumors were included in this study. A single-slice dynamic CT was performed after an intravenous bolus injection of contrast material (40 ml; 370 mg I/ml) at 8 ml/sec. The parameters were calculated on a pixel-by-pixel basis by using maximum slope method, and quantitative maps of arterial perfusion were created. Statistical correlation between tumor size, patient age, and perfusion were assessed. Differences in perfusion between scirrhous and nonscirrhous carcinoma were also assessed. RESULTS: Perfusion CT images were successfully created for 24 patients (mean age, 55.9 years old; range, 36-85 years). In five patients, dynamic CT was not performed due to lack of visualization of the breast tumor on unenhanced CT. In two patients, reliable perfusion CT image could not be created because of motion artifact. The mean perfusion for 24 tumors was 33.1 +/- 16.9 ml/min/100 ml (mean +/- SD; range, 14-78), and the tumor perfusion did not correlate with patient's age or tumor size (21.0 +/- 10.2 mm; range, 10-45 mm). The mean perfusion of nonscirrhous carcinoma (45.8 ml/min/100 ml; n = 11) was higher than that of scirrhous carcinoma (22.7 ml/min/100 ml; n = 11; P < .001). CONCLUSION: Determination of the perfusion of breast carcinoma is feasible by dynamic CT and can be performed during a routine CT study without much supplementary burden on the patient. There are differences in blood flow between scirrhous and nonscirrhous breast carcinoma, and further research is needed to determine the impact of this finding.
Subject(s)
Adenocarcinoma, Scirrhous/diagnostic imaging , Breast Neoplasms/diagnostic imaging , Neovascularization, Pathologic/diagnostic imaging , Tomography, X-Ray Computed/methods , Adenocarcinoma, Scirrhous/pathology , Adult , Aged , Aged, 80 and over , Artifacts , Breast Neoplasms/pathology , Contrast Media , Female , Humans , Injections, Intravenous , Iopamidol , Linear Models , Middle AgedABSTRACT
PURPOSE: To compare the accuracy of upper gastrointestinal (UGI) series and endoscopic examination in the diagnosis and localization of scirrhous gastric carcinoma. MATERIALS AND METHODS: Seventy-two patients with pathologically proved scirrhous gastric carcinoma in surgical specimens were included. Preoperative reports at UGI series and endoscopic examination, which included impressions on the location and extent of the tumor, were compared with pathology reports, and the accuracy of the preoperative reports was calculated. Two gastrointestinal radiologists retrospectively reviewed the appearance of mucosa at UGI series. RESULTS: Preoperative diagnoses at endoscopy were Borrmann type IV carcinoma in 28 patients (39%), type III carcinoma in 29 (40%), early gastric carcinoma in seven (10%), lymphoma in six (8%), atrophic gastritis in one (3%), and type II carcinoma in one (3%). Preoperative diagnoses at UGI series were type IV carcinoma in 44 patients (61%), type III carcinoma in 25 (35%), lymphoma in two (3%), and early gastric carcinoma in one (1%). Pathology reports were compared with the preoperative reports, and tumor location and extent were correct in the endoscopic examination reports of 24 patients (33%) and the UGI series reports of 49 patients (68%). In 68 patients, UGI series revealed thickened and irregular folds in 62 (91%), ulceration in 42 (62%), and nodularity in 22 (32%) at consensus review. Endoscopic biopsy samples were positive for malignancy in 66 patients (93%). CONCLUSION: UGI series is superior to endoscopic examination in the diagnosis and localization of scirrhous gastric carcinoma.
Subject(s)
Adenocarcinoma, Scirrhous/diagnosis , Gastroscopy , Stomach Neoplasms/diagnosis , Adenocarcinoma, Scirrhous/diagnostic imaging , Adult , Aged , Female , Humans , Male , Middle Aged , Radiography , Reproducibility of Results , Retrospective Studies , Stomach Neoplasms/diagnostic imagingABSTRACT
A 66-year-old male with massive ascites was diagnosed as advanced gastric scirrhous cancer at Musashino Red Cross Hospital. We detected the adenomatous cancer cells from his ascites, and an X-ray photograph of his stomach showed less capability of expansion in the upper gastrointestinal series. We attempted treatment with oral anticancer drug TS-1 with the patient's consent and achieved a long-term response of two years or more.
Subject(s)
Adenocarcinoma, Scirrhous/drug therapy , Antimetabolites, Antineoplastic/therapeutic use , Oxonic Acid/therapeutic use , Pyridines/therapeutic use , Stomach Neoplasms/drug therapy , Tegafur/therapeutic use , Adenocarcinoma, Scirrhous/diagnostic imaging , Aged , Drug Combinations , Humans , Male , Radiography, Abdominal , Remission Induction , Stomach Neoplasms/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
PURPOSE: To evaluate ultrasonographic (US) features in the differential diagnosis of giant gastric folds. MATERIALS AND METHODS: One hundred sixty-five patients with giant gastric folds at transabdominal US examination (five with Ménétrier disease, 24 with anisakiasis, 61 with acute gastric mucosal lesion [AGML], 13 with gastric lymphoma, and 62 with scirrhous carcinoma) were examined. With 3-6-MHz curved and 5-11-MHz linear-array transducers, the authors evaluated gastric wall thickness, wall stratification, main thickened layer, echogenicity, and compressibility of the lesion in each case. The Fisher protected least-significant-difference method was used to compare statistically the thickness of the gastric wall among diseases. RESULTS: Wall thickness of AGML was significantly (P <.001) less than that of anisakiasis, gastric lymphoma, and scirrhous carcinoma. US findings revealed regular gastric wall thickening of the second or third layer, with preservation of wall stratification in all patients with benign conditions. The fourth layer was thickened only in patients with malignancy. The echogenicity of gastric lymphoma was markedly lower than that of any other condition. Compressibility of scirrhous carcinoma was absent, whereas it was well preserved in all benign conditions. CONCLUSION: Transabdominal US can depict gastric wall stratification and is a useful noninvasive modality for differential diagnosis of giant gastric folds.
Subject(s)
Stomach/diagnostic imaging , Adenocarcinoma, Scirrhous/diagnostic imaging , Adolescent , Adult , Aged , Aged, 80 and over , Anisakiasis/diagnostic imaging , Child , Diagnosis, Differential , Female , Gastritis, Hypertrophic/diagnostic imaging , Gastroscopy , Humans , Lymphoma/diagnostic imaging , Male , Middle Aged , Stomach Diseases/diagnostic imaging , Stomach Neoplasms/diagnostic imaging , UltrasonographySubject(s)
Adenocarcinoma, Scirrhous/secondary , Breast Neoplasms/pathology , Muscle Neoplasms/secondary , Rectus Abdominis/pathology , Adenocarcinoma, Scirrhous/diagnostic imaging , Breast Neoplasms/surgery , Female , Humans , Mastectomy, Modified Radical , Middle Aged , Muscle Neoplasms/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
We present a rare case of four immunohistochemically different primary liver cancers developing in a 54-year-old Japanese man with chronic hepatitis C. In 1989, a liver tumor had been detected at another hospital during follow-up of hepatitis C virus (HCV) infection. He was first admitted to our hospital in July 1991, when a well defined hypervascular tumor, measuring 2.5 cm in diameter was found in the S5 subsegment of the liver on computed tomography (CT); S5 subsegmentectomy was therefore performed, in July 1991. Histopathological examination revealed scirrhous hepatocellular carcinoma (SHCC). Immunohistochemical analysis showed that the tumor was negative for mouse monoclonal anti-human hepatocyte antibody (Hep), but was partially positive for a mouse monoclonal antibody specific for cytokeratin 19 (CK19). Six years after the operation, a large tumor, measuring 10 cm in diameter, was found in the S4 subsegment and a 3-cm tumor was found in the caudate lobe on CT scans. Extended left hepatic lobectomy and partial resection of the caudate lobe were performed in August 1997. Histopathological examination revealed a moderately differentiated hepatocellular carcinoma (HCC) with a trabecular pattern, an SHCC with well differentiated HCC at its periphery, and a small incidental cholangiocellular carcinoma (CCC), measuring 1 cm in diameter. The HCC and CCC showed typical immunostaining for Hep and CK19, respectively. The SHCC was positive for both Hep and CK19, showing characteristics different from those of the previously resected SHCC on immunohistochemical analysis. In conclusion, we experienced four immunohistochemically different primary liver cancers in a patient with chronic hepatitis C.
Subject(s)
Adenocarcinoma, Scirrhous/diagnostic imaging , Adenocarcinoma, Scirrhous/pathology , Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/pathology , Cholangiocarcinoma/diagnostic imaging , Cholangiocarcinoma/pathology , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/pathology , Neoplasms, Multiple Primary/diagnostic imaging , Neoplasms, Multiple Primary/pathology , Humans , Male , Middle Aged , RadiographyABSTRACT
We employed interstitial brachytherapy using a high dose rate Ir-192 remote afterloading unit in two breast cancer patients with locoregional recurrence. In the first case, skin metastasis was treated, with favorable control of the infield tumor but subsequent persistent sequelae and multiple outfield metastases. This experience caused us to be cautious when choosing brachytherapy for the second case, in whom a solitary metastasis to an axillary lymph node was successfully treated. Although this method is still investigational, it may play a critical role in the treatment of locoregional recurrence resistant to other treatment modalities.
Subject(s)
Adenocarcinoma, Scirrhous/radiotherapy , Adenocarcinoma/radiotherapy , Brachytherapy/methods , Breast Neoplasms/radiotherapy , Iridium Radioisotopes/therapeutic use , Neoplasm Recurrence, Local/radiotherapy , Adenocarcinoma/diagnostic imaging , Adenocarcinoma, Scirrhous/diagnostic imaging , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Brachytherapy/instrumentation , Breast Neoplasms/diagnostic imaging , Female , Humans , Mastectomy , Neoplasm Recurrence, Local/diagnostic imaging , Neoplasm Staging , Patient Selection , Radiotherapy, Adjuvant , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
An effective shear modulus reconstruction technique is described which uses ultrasonic strain measurements for diagnosis of superficial tissues, i.e. our previously developed ultrasonic strain measurement and shear modulus reconstruction methods are combined and enhanced. The technique realizes very low computational load, yet yields fairly high quantitativeness, high stability and spatial resolution, and large dynamic range. The suitability of the method is demonstrated on in vitro pork ribs and in vivo human breast tissues (fibroadenoma and scirrhous carcinoma).
Subject(s)
Ribs/diagnostic imaging , Ultrasonography, Mammary/methods , Ultrasonography/methods , Adenocarcinoma, Scirrhous/diagnostic imaging , Animals , Elasticity , Fibroadenoma/diagnostic imaging , Humans , Models, Statistical , Phantoms, Imaging , SwineABSTRACT
A 68-year-old man was diagnosed as having a scirrhous cancer of the stomach. Carcinomatous peritonitis was suspected on abdominal CT examination. Three courses of uracil and tegafur (UFT)/cisplatin (CDDP) chemotherapy were administered. The primary foci were reduced in size, then total gastrectomy was performed. Histological findings revealed a poorly differentiated adenocarcinoma with scirrhous invasion into the subserosa. Histological efficacy of the chemotherapy was judged to be grade 2. The patient has been alive without disease for more than five years after total gastrectomy. Neoadjuvant chemotherapy with UFT and CDDP may have contributed to the favorable clinical outcome in this patient.